Atrial
Fibrillation

Atrial fibrillation is a heart rhythm disorder in which the upper chambers of the heart (the atria) quiver chaotically instead of contracting in a coordinated way. The lower chambers respond unpredictably, producing an irregular and often fast pulse that patients often describe as a "fluttering", "racing" or "irregular" heartbeat.

The chaotic atrial activity has two consequences: a less efficient heartbeat (reducing exercise tolerance by around 20–30%), and stagnant blood in pockets of the atrium where clots can form. If a clot is dislodged it can travel to the brain and cause a stroke. AFib is rarely directly life-threatening, but stroke prevention is the most important treatment goal.

In AFib, the upper heart chambers don't squeeze properly, so blood pools — particularly in a small pouch called the left atrial appendage. Stagnant blood forms clots, and if a clot breaks loose it travels in the bloodstream to the brain, blocks an artery and causes a stroke.

Strokes from AFib are typically larger and more disabling than other strokes because the clots are bigger. People with untreated AFib have around five times the stroke risk of those without — but with appropriate anticoagulation, that risk falls by approximately two-thirds, which is why anticoagulation is the cornerstone of AFib management.

Yes — episodes of paroxysmal AFib can stop spontaneously within minutes, hours or days, and an early first episode can sometimes never come back if a clear trigger (such as a binge drink, an infection or thyroid problem) is identified and removed.

However, if AFib has occurred once, it is more likely to occur again — and over time many patients progress from paroxysmal to persistent or permanent forms. Even when the rhythm self-resolves, the stroke risk while in AFib remains, which is why anticoagulation decisions are based on overall risk profile (CHA₂DS₂-VASc score), not just whether you are currently in AFib.

Anticoagulants ("blood thinners") reduce the risk of stroke in AFib by around two-thirds — one of the largest treatment effects in cardiovascular medicine. The decision to start one is based on the CHA₂DS₂-VASc score, which takes into account age, sex, blood pressure, diabetes, heart failure, vascular disease and previous stroke.

Modern direct oral anticoagulants (DOACs — apixaban, rivaroxaban, edoxaban, dabigatran) have largely replaced warfarin in UK practice. They require no blood-test monitoring, have fewer drug interactions, and carry a lower risk of brain bleeds. Aspirin is not an adequate substitute and is no longer recommended for stroke prevention in AFib.

Paroxysmal AFib comes and goes, with episodes lasting less than 7 days and stopping spontaneously. Persistent AFib lasts more than 7 days and usually requires medication or an electrical shock (cardioversion) to restore normal rhythm. Permanent AFib is AFib accepted as the baseline rhythm, with treatment focused on rate control and stroke prevention rather than rhythm correction.

The categories are clinically useful but the boundaries blur — many patients progress through them over time. Stroke risk is similar across all three categories, which is why anticoagulation decisions don't depend on the AFib subtype.

Yes — for most patients with well-controlled AFib, regular moderate exercise is encouraged and improves both symptoms and long-term outcomes. The exception is very intense endurance exercise, which can both trigger AFib episodes in susceptible people and accelerate the underlying heart remodelling that causes AFib in some athletes.

A sensible target is 150 minutes a week of moderate-intensity activity — walking, swimming, cycling, gardening — plus two sessions of resistance work. If your heart rate climbs unusually high during exercise on AFib, your medication may need adjusting. Speak to your cardiologist before significantly scaling back activity.

Common triggers include alcohol (especially binges — "holiday heart"), poor sleep, dehydration, stress, large meals, caffeine in susceptible individuals, and high-intensity exercise. Sleep apnoea is a particularly important and under-recognised trigger that is frequently missed.

Medical triggers include thyroid overactivity, electrolyte abnormalities, infections, post-surgical states and severe respiratory illness. Keeping a brief diary of episodes and likely triggers is one of the most useful things a patient can do — it often reveals patterns that genuinely change how the condition is managed.

Rate-control medication (typically a beta-blocker) is the first step for most patients with mild or well-tolerated AFib. Rhythm-control strategies — antiarrhythmic drugs or catheter ablation — are preferred for symptomatic patients, those with heart failure due to AFib, and increasingly for younger patients with paroxysmal AFib where ablation gives excellent long-term results.

Modern catheter ablation for paroxysmal AFib has a success rate of around 70–80% with one procedure and is now considered first-line therapy for many patients. Anticoagulation continues based on stroke risk regardless of which rhythm strategy is chosen — successful ablation does not by itself permit stopping anticoagulants in most patients.

Intermittent AFib is diagnosed by capturing an ECG during an episode. Tools include a 24-hour Holter monitor for daily symptoms, a 7-day patch monitor for less frequent episodes, and an implantable loop recorder — a small device under the skin that can monitor for up to three years — for rare but important episodes.

Modern smartwatches (Apple Watch, Fitbit, Withings ScanWatch) with built-in ECG capability are increasingly useful and can produce diagnostic-quality tracings. If you have unexplained palpitations or have had a stroke without an obvious cause, prolonged rhythm monitoring is strongly worth considering.

Yes — alcohol is one of the strongest modifiable risk factors for AFib. A binge of any amount can provoke an episode in susceptible people ("holiday heart"), and regular drinking of more than around 14 units a week roughly doubles the risk of developing chronic AFib.

Importantly, reducing alcohol intake reduces AFib episodes. A randomised trial showed that cutting alcohol from 17 to 2 units a week roughly halved AFib recurrence in symptomatic patients. For anyone with AFib, reducing or stopping alcohol is one of the highest-yield lifestyle interventions available.